Immune Gene Prevents Parkinson's And Dementia

Immune Gene Prevents Parkinson's And Dementia
An estimated seven to ten million people worldwide are living with Parkinson's disease (PD), which is an incurable and progressive disease of the nervous system affecting movement and cognitive function. More than half of PD patients develop progressive disease showing signs of dementia similar to Alzheimer's disease. Researchers have now discovered that non-inheritable PD may be caused by functional changes in the immune regulating gene Interferon-beta (IFNβ). Treatment with IFNβ successfully prevented neuronal death and disease effects in an experimental model of PD. The results have been published in Cell.

Protein regulates waste management in nerve cells
The human brain consists of approximately 100 billion neurons, which coordinate activities in all parts of the body. Now, researchers have discovered that the immune gene IFNβ plays a vital role in keeping neurons healthy.
 
"We found that IFNβ is essential for neurons ability to recycle waste proteins. Without this, the waste proteins accumulate in disease-associated structures called Lewy bodies and with time the neurons die", the researchers explained.
 
The research team found that mice missing IFNβ developed Lewy bodies in parts of the brain, which control body movement and restoration of memory, and as a result they developed disease and clinical signs similar to patients with PD and dementia with Lewy bodies (DLB).

New understanding of non-familial Parkinson's disease
While hereditary gene mutations have long been known to play a role in familial PD, the study offers one of the first models for so-called non-familial PD, which comprises the majority (90-95%) of patients suffering from PD.
 
According to the researchers, the new knowledge opens new therapeutic possibilities:
"This is one of the first genes found to cause pathology and clinical features of non-familial PD and DLB, through accumulation of disease-causing proteins. It is independent of gene mutations known from familial PD and when we introduced IFNβ-gene therapy, we could prevent neuronal death and disease development. Our hope is that this knowledge will enable development of more effective treatment of PD".
 
Current treatments are effective at improving the early motor symptoms of the disease, however, as the disease progress, the treatment effect is lost. The next step for the research team will be to gain a better understanding of the molecular mechanisms by which IFNβ protects neurons and thereby prevents movement disorders and dementia.
 
If you appreciate our work, consider making a contribution